New International Funding for CMD Research

Original story from the University of Melbourne Dr. Avnika Ruparelia of the University of Melbourne has received new international funding to advance her research in congenital muscular dystrophy. The grant, from the French neuromuscular research organization AFM-Téléthon, supports her work on muscle stem cells and new treatment approaches for LAMA2-Related Dystrophy (LAMA2-RD).
She leads the Ruparelia Laboratory at the University of Melbourne’s Centre for Muscle Research, where her team uses zebrafish and other models to understand how congenital muscular dystrophies develop and to search for therapies that improve muscle function.
Dr. Ruparelia’s new project uses zebrafish to learn why muscle stem cells, the cells that repair damaged muscle, stop working properly in LAMA2-RD. The team is also searching for treatments that could protect muscle and support repair.
Dr. Ruparelia describes the work as a complementary approach, one that aims to help the body “repair and maintain muscle throughout life.”
The project is among the first in the world to study how muscle stem cells contribute to LAMA2-RD and whether targeting them could become a treatment strategy. While much of the field is focused on gene therapy, Dr. Ruparelia notes that combination therapies will likely be needed for the best outcomes, and improving muscle repair after damage has occurred could complement those efforts. The findings may also help other muscle diseases with similar underlying biology. Want to hear more from Dr. Ruparelia? Watch our CMD Researcher Spotlight, where she explains how zebrafish help researchers understand CMD and test potential treatments.
Read the full article on the University of Melbourne’s website. Full credit and our appreciation, not only to Dr. Ruparelia and the members of her lab, but also The University of Melbourne.
The research that led to this project was funded, in part, by Cure CMD through donations from our generous supporters. Learn more about Cure CMD’s research strategy and funding portfolio.
